ESH Video


August 30, 2022

6th Translational Research Conference



October 7-9, 2022
Mandelieu-La Napoule, France


Chairs: Maria-Victoria Mateos (Salamanca), Philippe Moreau (Nantes),
Vincent Rajkumar (Rochester)


You are eligible if you are:

September 15th, 2022

The ESH Scholarship Fund is a multi-sponsored project designed to support access to new biological and clinical data in the context of lifelong learning in Haematology.

- ESH independently ensures all scientific peer review and selection procedures.
- ESH is also independently responsible for all administrative aspects of the Fund.

Register now and join our international faculty of renowned experts
in the beautiful city of the French Riviera,
Mandelieu-La Napoule!


About the Conference:

An outstanding faculty of distinguished global experts will present the most recent advances and new perspectives in the field of Multiple Myeloma and plasma disorders, from pathophysiology to diagnosis and therapy, including current challenges and new perspectives.

The plenary conference programme is designed to place emphasis on leading-edge basic and clinical research. The presentation of unpublished data is encouraged. Ample time is deliberately provided for in-depth scientific discussion and interaction. Registered participants will further benefit from a variety of opportunities for informal scientific interaction with the world’s leading experts in the field, including during small Meet the Expert sessions and Mentored Posters Walks.

Conference main topics:
• Smoldering Myeloma
• Diagnosis of Multiple Myeloma
• Frontline therapy in patients not eligible for autologous stem cell transplantation
• Frontline therapy in patients eligible for autologous stem cell transplantation
• MRD and the Microenvironment
• Relapsed Multiple Myeloma
• The Future: Recent Clinical Trials in Relapse
• Data Management Issues
• Plasma Cell Disorder

Learning objectives:
• Update on the pathophysiology of myeloma and how the disease is evolving from MGUS and SMM
• Update on the diagnostic criteria and the use of new assessments in the diagnostic process
• Treatment of young myeloma patients
• Treatment of elderly and frail myeloma patients
• Optimal sequencing at the relapse
• To know what is the role of new immunotherapic approaches and how will they fit in the landscape
• Role of novel drugs under development
• Latest updates in other plasma cell disorders beyond myeloma

For more information, click here!

To meet the faculty, click here!

With the support of*:

Premium Conference Partner

Diamond Conference Partner

Emerald Conference Partner

Ruby Conference Partner

*ESH conference programmes are developed in strict scientific independence
with no input from corporate sponsors.